Overview

Study of Combination of Cetuximab and Radiotherapy Added to the Standard Treatment for Oesophageal Adenocarcinoma

Status:
Terminated
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether the addition of the combination between cetuximab and radiotherapy to the standard chemotherapy for resectable oesophageal cancer is safe and adds efficacy.
Phase:
Phase 2
Details
Lead Sponsor:
P.O. Witteveen
UMC Utrecht
Collaborators:
Merck KGaA
Merck KGaA, Darmstadt, Germany
Treatments:
Cetuximab